Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 331-333

  Paule, Bernard ^a   Brion, Nathalie ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Chromophobe renal cell carcinoma; Interferon; MTOR; Sorafenib; Temsirolimus

Indexed keywords

ALPHA2A INTERFERON; SORAFENIB; TEMSIROLIMUS;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; GENERAL CONDITION; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; SALVAGE THERAPY; SIROLIMUS; TREATMENT OUTCOME;

EID: 79851482968     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol 33: 534-543, 2006.
2. Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A and Menon M: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 26: 281-291, 2002. (Pubitemid 34184451)
3. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M and Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non clear-cell histology. J Clin Oncol 20: 2376-2381, 2002. (Pubitemid 34441667)
4. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM and Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26: 127-131, 2008.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
7. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J and Bukowski R: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763, 2009.
8. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
9. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G and Milella M: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554, 2006. (Pubitemid 43927103)
10. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006. (Pubitemid 43050086)
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007. (Pubitemid 46849157)
12. J Ljungberg B, Cowa N, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Mulders PFA, Patard J-J and Sinescu IC: Guidelines on renal cell carcinoma. European Association of Urology. http://www.uroweb.org/?id=218&gid=4, 2010.
13. Jiang BH and Liu LZ: PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158, 2008.
14. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J and Hudes G: Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26: 202-209, 2009.
15. Petit A, Castillo M, Santos M, Mellado B, Alcover JB and Mallofré C: KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 28: 676-678, 2004. (Pubitemid 38579572)
16. Dudek AZ, Zolnierek J, Dham A, Lindgren BR and Szczylik C: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115: 61-67, 2009.
17. Sablin MP, Négrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J and Escudier B: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34, 2009.
18. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
19. Lane HA and Breuleux M: Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 21: 219-229, 2009